Brad Savall's Research Focus
Dr. Savall has been involved in the discovery of new medicines for over 15 years across several therapeutic areas including neuroscience, immunology/inflammation, metabolic disease, and oncology. Since joining the team at SBP, Brad has focused on identifying novel chemical compounds from the HTS screening campaigns and evolving those initial hits into potent and selective drug-like leads with good physical chemical properties. Brad is currently leading the medicinal chemistry efforts at SBP on Chemical Biology Consortium-funded cancer intervention programs targeting novel oncogenic metabolic pathways.
Brad Savall's Bio
Dr. Savall is an accomplished drug discovery scientist with expertise in medicinal and synthetic chemistry. Prior to joining SBP, Dr. Savall worked for 14 years within the Janssen pharmaceutical companies of Johnson & Johnson. He was directly responsible for the discovery of three clinical candidates, including the first clinically used histamine H4 receptor for atopic dermatitis and a P2X7 receptor antagonist for treatment-resistant depression. Dr. Savall has led drug discovery programs in both immunology and neuroscience (CNS), which delivered several additional clinical candidates. Dr. Savall was the chemistry team leader for the AMPA TARP program, which targeted a novel protein-protein interaction (PPI) as a potential treatment for epilepsy and other CNS disorders. He has been involved in multiple programs from the early stages of initial screening and target validation, to hit to lead, lead optimization, and profiling and delivery of clinical candidates. He has significant experience in crafting IP strategies for chemical matter in multiple disease areas and has been involved in several due diligence analyses.
Prior to joining Janssen, Dr. Savall worked on discovering new modalities for the treatment of diabetes and obesity at Amylin pharmaceuticals. He received his Ph.D. from the Department of Chemistry at the University of Michigan under the Direction of Professor William R. Roush.
- Chemistry leader for an SBP oncology target currently partnered with the Chemical Biology Consortium (CBC).
- Project leader for several drug discovery programs, which delivered multiple clinical candidates across two therapeutic areas.
- Team lead for AMPA TARP/gamma-8 modulator program from inception of program to delivery of highly potent modulators suitable as a clinical candidates.
- Led effort and directly discovered JNJ-5446, a first-in-class brain-penetrant clinical candidate that modulates the P2X7 ion-channel.
- Led team and directly discovered JNJ-8979; the first histamine H4 receptor antagonist to demonstrate human target clinical efficacy.
- Discovered clinical candidate JNJ-3100, a potent and highly selective LTA4 Hydrolase inhibitor for the treatment of chronic asthma.
- Authored over 40 publications and presentations, and an inventor on over 20 patents / patent applications.
- Associate editor of Medicinal Chemistry Reviews.